Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor

Cellular Immunology

Volumn 259, Issue 2, 2009, Pages 117-127

  Ge, Lisheng ^a   Zhang, Jian Gang ^a,b   Samathanam, Christina A ^a,b   Delgado, Christina ^a   Tarbiyat Boldaji, Mary ^a   Dan, Qinghong ^a,b   Hoa, Neil ^a   Nguyen, Tuong Vi ^a   Alipanah, Reza ^a   Pham, Jimmy T H ^a   Sanchez, Ramon ^a   Wepsic, H Terry ^a,b   Morgan, Timothy R ^a,b   Jadus, Martin R ^a,b,c  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alt macrophage colony stimulating factor; Autoimmunity; Cytotoxic T lymphocytes; Hepa1 6; Hepatocellular carcinoma; HepG2; Macrophage colony stimulating factor; RMA S; Tumor immunity

Indexed keywords

COLONY STIMULATING FACTOR 1; PEPTIDE DERIVATIVE;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HEPATITIS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOHISTOLOGY; KIDNEY CELL; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

MURINAE; MUS;

EID: 70349178668     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.06.008     Document Type: Article

References (54)

1. Michielsen P.P., Francque S.M., and van Dongen J.L. Viral hepatitis and hepatocellular carcinoma. World J. Surg. Oncol. 3 (2005) 27-35
2. Butterfield L.H., Koh A., Meng W., Vollmer C.M., Ribas A., Dissette V., Lee E., Glaspy J.A., McBride W.H., and Economou J.S. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from α-fetoprotein. Cancer Res. 59 (1999) 3134-3142
3. Vollmer Jr. C.M., Eilber F.C., Butterfield L.H., Ribas A., Dissette V.B., Koh A., Montejo L.D., Lee M.C., Andrews K.J., McBride W.H., Glaspy J.A., and Economou J.S. α-Fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 59 (1999) 3064-3067
4. Engvall E., Pihko H., Jalanko H., and Ruoslahti E. Effect of specific immunotherapy with preimmunization against alpha-fetoprotein on a mouse transplantable hepatoma. J. Natl. Cancer Inst. 59 (1977) 277-280
5. + T cell epitope from hepatocellular carcinoma-associated antigen HCA587. Clin. Exp. Immunol. 140 (2005) 310-319
6. Yamashita N., Ishibashi H., Hayashida K., Kudo J., Takenaka K., Itoh K., and Niho Y. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology 24 (1996) 1437-1440
7. Kobayashi Y., Higashi T., Nouso K., Nakatsukasa K., Ishizaki H.M., Kaneyoshi T., Toshikuni N., Kariyama K., Nakayama E., and Tsuji T. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J. Hepatol. 32 (2000) 612-617
8. + T cell responses in patients with hepatocellular carcinoma. J. Immunol. 174 (2005) 1709-1716
9. Chen Z., Shao J.B., and Wu W. Expression of A, G and B melanoma antigen genes in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 1 (2002) 570-573
10. Luo G., Huang S., Xie X., Stockert E., Chen Y.T., Kubuschok B., and Pfreundschuh M. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun. 2 (2002) 11
11. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., Kuzushima K., Takiguchi M., and Kaneko S. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43 (2006) 1284-1294
12. Ikeguchi M., Ueda T., Sakatani T., Hirooka Y., and Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diag. Mol. Path. 11 (2002) 33-40
13. Andersen M.H., Pedersen L.Ø., Becker J.C., and Straten P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Can. Res. 61 (2000) 869-872
14. Covini G., Chan E.K., Nishioka M., Morshed S.A., Reed S.I., and Tan E.M. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 25 (1997) 75-80
15. Knights A.J., Zaniou A., Rees R.C., Pawelec G., and Müller L. Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol. Immunother. 51 (2002) 271-281
16. Ladhams A., Schmidt C., Sing G., Butterworth L., Fielding G., Tesar P., Strong R., Leggett B., Powell L., Maddern G., Ellem K., and Cooksley G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J. Gastroenterol. Hepatol. 17 (2002) 889-896
17. Friedl J., Stift A., Paolini P., Roth E., Steger G.G., Mader R., Jakesz R., and Gnant M.F.X. Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer. Cancer Biother. Radiopharm. 15 (2000) 477-480
18. Lee W.C., Wang H.C., Hung C.F., Huang P.F., Lia C.R., and Chen M.F. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J. Immunother. 28 (2005) 496-504
19. Peng S.Y., Chen W.J., Lai P.L., Jeng Y.M., Sheu J.C., and Hsu H.C. High α-fetoprotein level correlates with high stage, early recurrence poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection age p53 and β-catenin mutations. Int. J. Cancer 112 (2004) 44-50
20. Koga H., Sakisaka S., Ohishi M., Kawaguchi T., Taniguchi E., Sasatomi K., Harada M., Kusaba T., Tanaka M., Kimura R., Nakashima Y., Nakashima O., Kojiro M., Kurohiji T., and Sata M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29 (1999) 688-696
21. Kakumu S., Okumura A., Ishikawa T., Yano M., Enomoto A., Nishimura H., Yoshioka K., and Yoshika Y. Serum levels of IL-15, IL-10 and soluble tumor necrosis factor-α receptors in type C chronic liver disease. Clin. Exp. Immunol. 109 (1997) 458-463
22. Semeniuk D.J., Boismenu R., Tam J., Weissenhofer W., and Murgita R.A. Evidence that immunosuppression is an intrinsic property of the alpha-fetoprotein molecule. In: Atassi M.Z., and Bixler G.S. (Eds). Immunobiology of Proteins and Peptides VIII (1995), Plenum Press, New York 255-269
23. Tsai J.F., Jeng J.E., Chuang L.Y., Yang M.L., Ho M.S., Chang W.Y., Hsieh M.Y., Lin Z.Y., and Tsai J.H. Elevated urinary transforming growth factor β1 level as a tumor marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Brit. J. Cancer 76 (1997) 244-250
24. Ninomiya T., Akbar S.M., Masumoto T., Horiike N., and Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J. Hepatol. 31 (1999) 323-331
25. Kakumu S., Ito S., Ishikawa T., Mita Y., Tagaya T., Fukuzawa Y., and Yoshioka K. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J. Gastroenterol. Hepatol. 15 (2001) 431-436
26. Nawrocki S., and Mackiewicz A. Genetically modified tumor vaccines - where we are today. Cancer Treat. Rev. 25 (1999) 29-46
27. Heath W.R., Belz G.T., Behrens G.M.N., Smith C.M., Forehan S.P., Parish I.A., Davey G.M., Wilson N.S., Carbone F.R., and Villadangos J.A. Cross-presentation dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199 (2004) 9-26
28. Rock K.L., and Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 199 (2007) 166-183
29. Dan Q., Sanchez R., Delgado C., Wepsic H.T., Morgan K., Chen Y., Jeffes E.W.B., Lowell C.A., Morgan T.R., and Jadus M.R. Non-immunogenic murine hepatocellular carcinoma Hepa1-6 cells expressing the membrane form of macrophage colony stimulating factor are rejected in vivo and lead to CD8 T cell immunity against the parental tumor. Mol. Ther. 4 (2001) 427-437
30. Probst-Kepper M., Stroobant V., Kridel R., Gaugler B., Landry C., Brasseur F., Cosyns J.P., Weynand B., Boon T., and Van Den Eynde B.J. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J. Exp. Med. 193 (2001) 1189-1198
31. Probst-Kepper M., Hecht H.J., Herrmann H., Janke V., Ocklenburg F., Klempnauer J., van den Eynde B.J., and Weiss S. Conformational restraints and flexibility of 14-meric peptides in complex with HLA-B*3501. J. Immunol. 173 (2004) 5610-5616
32. Hoa N., Zhang J.G., Delgado C., Myers M.P., Callahan L.L., Vandeusen G., Schiltz P.M., Wepsic H.T., and Jadus M.R. BK channel activation results in paraptosis: a possible mechanism to explain monocyte-mediated killing of tumor cells expressing membrane macrophage colony stimulating factor. Lab. Invest. 87 (2007) 115-129
33. Hoa N., Myers M.P., Zhang J.G., Delgado C., Driggers L., Callahan L.L., Vandeusen G., Schiltz P.M., Wepsic H.T., Douglass T.G., Pham J.T.H., Bhakta N., Ge L., and Jadus M.R. Molecular mechanisms of paraptosis induction: implications for a non-genetic modified tumor vaccine. PLoS One 4 (2009) e4631
34. Schumacher T.N.M., Heemels M.T., Neefjes J.J., Kast W.M., Melief C.J.M., and Ploegh H.L. Direct binding of peptide to empty MHC class I molecules on intact cell and in vitro. Cell 62 (1990) 563-567
35. DeSilva A.D., Boesteanu A., Song R., Nagy N., Harhaj E., and Harding C.V. Thermolabile H-2K molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by low-affinity peptides. J. Immunol. 163 (1999) 4413-4420
36. Jeffes E.W.B., Zhang J.G., Hoa N., Pektar A., Delgado C., Chong S., Obenaus A., Sanchez R., Khalaghizadeh S., Khomenko T., Knight B.A., Alipanah R., Nguyen T.V., Shah C., Vohra S., Zhuang J.L., Liu J., and Wepsic H.T. Anti-angiogenic drugs synergize with a membrane macrophage colony stimulating factor based tumor vaccine to therapeutically treat rats with an established intracranial malignant glioma. J. Immunol. 174 (2005) 2533-2543
37. Ledbetter J.A., Seaman W.E., Tsu T.T., and Herzenberg L.A. Lyt-2 and Lyt-3 antigens are on two different polypeptide subunits linked by disulfide bonds: relationship of subunits to T cell cytotoxic activity. J. Exp. Med. 153 (1981) 1503-1516
38. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 (2001) e45
39. Zhang J.G., Eguchi J., Kruse C.A., Gomez G.G., Fakhrai H., Schroter S., Ma W., Hoa N., Minev B., Delgado C., Wepsic H.T., Okada H., and Jadus M.R. Antigenic profiles of glioma cells to generate allogeneic vaccines or DC-based therapeutics. Clin. Can. Res. 13 (2007) 566-575
40. Darlington G.J. Liver cell lines. Methods Enzymol. 151 (1987) 19-38
41. Savarese D.M., Valinski H., Quesenberry P., and Savarese T. Expression and function of colony-stimulating factors and their receptors in human prostate carcinoma cell lines. Prostate 34 (1998) 80-91
42. Paietta E., Racevskis J., Stanley E.R., Andreeff M., Papenhausen P., and Wiernik P.H. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res. 50 (1999) 2049-2055
43. Kirma N., Hammes L.S., Liu Y.G., Nair H.B., Valente P.T., Kumar S., Flowers L.C., and Tekmal R.R. Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression. Cancer Res. 67 (2007) 1918-1926
44. Smith H.O., Anderson P.S., Kuo D.Y., Goldberg G.L., DeVictoria C.L., Boocock C.A., Jones J.G., Runowicz C.D., Stanley E.R., and Pollard J.W. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin. Cancer Res. 1 (1995) 313-325
45. Kacinski B.M., Scata K.A., Carter D., Yee L.D., Sapi E., King B.L., Chambers S.K., Jones M.A., Pirro M.H., Stanley E.R., and Rohrschneider L.R. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 6 (1991) 941-952
46. Ramakrishnan F., Xu J., Brandt S.J., Niedel J.E., Bast R.C., and Brown E.L. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J. Clin. Invest. 83 (1989) 921-926
47. Nakatsuka K., Sugiyama H., Nakagawa Y., and Takahashi H. Purification of antigenic peptide from murine hepatoma cells recognized by class I major histocompatibility complex molecule restricted cytotoxic T lymphocytes induced with B7-1 gene transfected hepatoma cells. J. Hepatol. 30 (1999) 1119-1129
48. Tamaki S., Homma S., Enomoto Y., Komita H., Zeniya M., Ohno T., and Toda G. Autoimmune hepatic inflammation by vaccination of mice with dendritic cells loaded with well-differentiated hepatocellular carcinoma cells and administration of interleukin-12. Clin. Immunol. 117 (2005) 280-293
49. Su H., Lu R., Ding R., and Kan Y.W. Adeno-associated viral-mediated gene transfer to hepatoma: thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals. Mol. Ther. 1 (2000) 509-515
50. Stonans I., Stonane E., Rußwurm S., Deigner H.P., Böhm K.J., Wiederhold M., Jäger L., and Reinhart K. HepG2 human hepatoma cells express multiple cytokine genes. Cytokine 11 (1999) 151-156
51. Rowell D.L., Eckmann L., Dwinell M.B., Carpenter S.P., Raucy J.L., Yang S.K., and Kagnoff M.F. Human hepatocytes express an array of pro-inflammatory cytokines after agonist stimulation or bacterial invasion. Am. J. Physiol. Gastrointest. Liver Physiol. 273 (1997) G322-G332
52. Yang W., Wu K., Zhao M., Zhang L., Zhang L., Song N., and Song Y. Co-expression of macrophage colony-stimulating factor with its receptor in human hepatoma cells and its potential roles. Chin. J. Cancer Res. 11 (1999) 79-84
53. Song Y.H., Lin Y.M., Wu K., Yang W.Q., Li G., and Zheng D.X. Immunohistochemical observation of macrophage colony stimulating factor and its receptor in breast cancer and hepatoma tissues. Chin. J. Cancer Res. 13 (2001) 1-4
54. Williams C.C., Trinh H., Tran T.V., Dan Q., Sanchez R., Delgado C., Chen Y., Jeffes E.W.B., Wepsic H.T., and Jadus M.R. Membrane expression of macrophage colony stimulating factor on MADB106 breast cancer cells are not directly killed by macrophages in vitro, but lead to tumor rejection in vivo and immunizes against MADB106 parental cells. Mol. Ther. 3 (2001) 216-224